Mycoses in AIDS

References

• Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 1991; 5: 519–525.
   PubMed Web of Science ®Google Scholar
• Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989; 18: 554–564.
   PubMed Web of Science ®Google Scholar
• Sangeman JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339–346.
   PubMed Web of Science ®Google Scholar
• Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in 0 2000 ISHAM, Medical Mycology, 38, Suppl. I, 259-267 patients with AIDS: Prevalence and microbiology. Clin Infect Dis 1997; 24: 28–34.
   Google Scholar
• Millon L, Manteaux A, Reboux G, et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: Persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994; 32: 1115–1118.
   PubMed Web of Science ®Google Scholar
• Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1–8.
   PubMed Web of Science ®Google Scholar
• Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida albicans in patients with recurrent oropharyngeal can-didosis and human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993; 37: 2449–2453.
   PubMed Web of Science ®Google Scholar
• Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994; 8: 787–792.
   PubMed Web of Science ®Google Scholar
• Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of carriage of fluconazole-resistant Candida in the oropharynx of HIV-Infected patients. Clin Infect Dis 1997; 25: 843–846.
   PubMed Web of Science ®Google Scholar
• Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 219–225.
   PubMed Web of Science ®Google Scholar
• Powderly WG. Resistant candidiasis. AIDS Res Hun Retro-viruses 1994; 10: 925–929.
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Li TS, et al. Positive effects of com-bined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112–116.
   PubMed Web of Science ®Google Scholar
• Pakker NG, Roos MT, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retro-virol 1997; 16: 318–326.
   PubMedGoogle Scholar
• Angel JB, Kuman A, Parato K, et al. Improvement in cell-me-diated immune functions during potent anti-human im-munodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998; 177: 898–904.
   PubMed Web of Science ®Google Scholar
• Can A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1 associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351: 256–261.
   Google Scholar
• Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996; 334: 1674–1675.
   PubMed Web of Science ®Google Scholar
• Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic disease with combination antiretroviral therapy. 5th Conference on Retroviruses and Opportunistic Infec-tions, Chicago, February 1–5, 1998. Abstract 184.
   Google Scholar
• Centers for Disease Control and Prevention. Update: Trends in AIDS incidence 1996. MMWR 1997; 46: 861–867.
   PubMedGoogle Scholar
• Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of oppor-tunism? JAMA 1998; 280: 72–77.
   Google Scholar
• Hicks CB, Myers SA, Giner J. Resolution of intractable mollus-cum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. Clin Infect Dis 1997; 24: 1023–1025.
   Google Scholar
• Can A, Cooper DA Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease in-hibitor [letter]. Lancet 1997; 349: 995–996.
   Google Scholar
• Elliot B, Aromin I, Gold R, Flanigan T, Mileno M. 2.5 year remission of AIDS-associated progressive multifocal leukoen-cephalopathy with combined antiretroviral therapy [letter]. Lancet 1997; 349: 850.
   Google Scholar
• Power C, Nath A, Aoki FY, Bigio MD. Remission of progres-sive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection [letter]. N Engl J Med 1997; 336: 661–662.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Inves-tigators. N Engl J Med 1998; 338: 853–860.
   PubMedGoogle Scholar
• Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Euro-SIDA Study Group. Lancet 1998; 352: 1725–1730.
   PubMed Web of Science ®Google Scholar
• Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179: 717–720.
   Google Scholar
• Sepkowitz KA Effect of HAART on natural history of AIDS-related opportunistic disorders. fancet 1998; 351: 228–230.
   Google Scholar
• Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27: 1291–1294.
   PubMed Web of Science ®Google Scholar
• Hood S, Bonington A, Evans J, Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 1998; 12: 447–448.
   PubMed Web of Science ®Google Scholar
• Valdez H, Gripshover BM, Salata RA, Lederman MM. Resolu-tion of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS 1998; 12: 538.
   PubMedGoogle Scholar
• Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration: multicenter AIDS cohort study investigators. JAMA 1998; 280: 1497–1503.
   PubMed Web of Science ®Google Scholar
• Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie El. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998; 42: 129–134.
   Google Scholar
• Can A, Cooper DA. HIV protease inhibitors. AIDS 1996; 10 (Suppl. A): 151–157.
   Google Scholar
• Flexner C. HIV protease inhibitors. N Engl J Med 1998; 338: 1281–1292.
   PubMed Web of Science ®Google Scholar
• Hube B. Candida albicans secreted aspartyl proteinases. Curr Top Med Mycol 1996; 7: 55–69.
   PubMedGoogle Scholar
• Cassone A, De Bemardis F, Mondello F, Ceiddia T, Agatensi L. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 1987; 156: 777–783.
   PubMed Web of Science ®Google Scholar
• De Bemardis F, Arancia S, Morelli L, et al. Evidence that members of the secretory aspartyl proteinases gene family (SAP), in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999; 179: 201–208.
   PubMedGoogle Scholar
• Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180: 448–453.
   PubMed Web of Science ®Google Scholar
• Korting HC, Schaller M, Eder G, et al. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected pa-tients. Antimicrob Agents Chemother 1999; 43: 2038–2042.
   PubMed Web of Science ®Google Scholar
• Cauda R, Tacconelli E, Tumbarello M, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 21: 20–25.
   Google Scholar
• Gottfredsson M, Cox GM, Indridason OS, de Almeida GM, Heald AE, Perfect JR. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Can-dida colonization. J Infect Dis 1999; 180: 534–537.
   Google Scholar
• Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339: 33–39.
   PubMed Web of Science ®Google Scholar
• Pietrella D, Monari C, Retini C, Palazzetti B, Bistoni F, Vecchiarelli A. Human immunodeficiency virus 1 envelope protein gp120 impairs intracellular antifungal mechanisms in human monocytes. J Infect Dis 1998; 177: 347–354.
   PubMedGoogle Scholar
• Gruber A, LukasserVogl E, Borg-von Zepelin M, Dierich MP, Wrzner R. Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J Infect Dis 1998; 177: 1057–1063.
   Google Scholar
• Gea-Banacloche JC, Clifford Lane H. Immune reconstitution in HIV infection. AIDS 1999; 13 (Suppl A): 525–S38.
   Google Scholar
• Dromer F, Lortholary 0, Mathoulin S, Dupont B and the French Cryptococcosis Study Group. Clinical and biological aspects of cryptococcosis in France. 14th ISHAM Congress, Buenos Aires, Argentina, May 8–12, 2000.
   Google Scholar
• Kovacs JA, Masur H. Prophylaxis against opportunistic infec-tions in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342: 1416–1429.
   PubMed Web of Science ®Google Scholar
• McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole pro-phylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-con-trolled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28: 1049–1056.
   PubMed Web of Science ®Google Scholar
• Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with cloftimazole troches for the prevention of fungal infections in patients with advanced hu-man immunodeficiency virus infection. N Engl J Med 1995; 332: 700–705.
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clini-cal Trials Group. N Engl J Med 1995; 332: 693–699.
   PubMed Web of Science ®Google Scholar
• Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 1999; 180: 1969–1978.
   PubMed Web of Science ®Google Scholar
• Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999; 340: 1301–1306.
   PubMed Web of Science ®Google Scholar
• Schneider MM, Borleffs JC, Stolk RP, Jaspers CA, Hoepelman AI. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy. Lancet 1999; 353: 201–203.
   Google Scholar
• Weverling GJ, Mocroft A, Lederberger B, et al. Discontinua-tion of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Eu-roSIDA Study Group. Lancet 1999; 353: 1293–1298.
   PubMed Web of Science ®Google Scholar
• Yangco BG, Von Bargen JC, Moorman AC, Holmberg SD. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpa-tient Study (HOPS) Investigators. Ann Intern Med 2000; 132: 201–205. @ 2000 ISHAM, Medicd Mycology, 38, Suppl. I, 259-267
   Google Scholar
• Woods CW, McRill C, Plikaytis BD, et al. Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. J Infect Dis 2000; 181: 1428–1434.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Price RW, Heeren DM, Pearce RB, Bredt B. Discon-tinuation of antifungal therapy for cryptococcosis after im-munologic response to antiretroviral therapy. Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000: Abstract 123.
   Google Scholar
• Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118: 610–616.
   PubMed Web of Science ®Google Scholar
• Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339: 1739–1743.
   PubMed Web of Science ®Google Scholar
• Lortholary 0, Denning DW, Dupont B. Endemic mycoses: a treatment update. J Antimicrob Chemother 1999; 43: 321–331.
   Google Scholar
• Wheat J. Endemic mycoses in AIDS: A clinical review. Clin Microbiol Rev 1995; 8: 146–159.
   PubMedGoogle Scholar
• Johnson PC, Kardori N, Najjar A, et al. Progressive dissemi-nated histoplasmosis in patients with acquired immunodefi-ciency syndrome. Am J Med 1988; 88: 152–158.
   Google Scholar
• McKinsey DS, Spiegel RA, Hutwagner L, et al. Prospective study of histoplasmosis in patients infected with human im-munodeficiency virus: Incidence, risk factors, and pathophysiol-ogy. Clin Infect Dis 1997; 24: 1195–1203.
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Dissemi-nated histoplasmosis in the acquired immunodeficiency syn-drome: clinical findings, diagnosis, and treatment, and review of the literature. Medicine (Baltimore) 1990; 69: 361–374.
   PubMed Web of Science ®Google Scholar
• Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 1990; 69: 384–391.
   PubMed Web of Science ®Google Scholar
• Ampel NM, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospec-tive study in a coccidioidal endemic area. Am J Med 1993; 94: 235–240.
   Google Scholar
• Singh VR, Smith DK, Lawrence J, et al. Coccidioidomycosis in patients with human immunodeficiency virus, review of 91 cases at a single institution. Clin Infect Dis 1996; 2: 563–568.
   Google Scholar
• Jones JL, Fleming PL, Ciesielski CA, et al. Coccidioidomycosis among persons with AIDS in the United States. J Infect Dis 1995; 171: 961–966.
   PubMed Web of Science ®Google Scholar
• Wheat J, Hafner R, Korzun A, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired im-munodeficiency syndrome. Am J Med 1995; 98: 336–342.
   PubMed Web of Science ®Google Scholar
• Hecht FM, Wheat J, Korzun AH, et al. Itraconazole mainte-nance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Def S Human Retrovirol 1997; 16: 100–107.
   PubMedGoogle Scholar
• McNeil MM, Ampel NM. Opportunistic coccidioidomycosis in patients with human immunodeficiency virus prevention issues and priorities. Clin Infect Dis 1995; 21 (Suppl. 1): 5111–S113.
   Google Scholar
• Johnson P, Wheat L, Cloud G, et al. A multicenter rendomized trial comparing amphotericin B and liposomal amphotericin B (AmBisome) as induction therapy of disseminated histoplasmo-sis in AIDS patients. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 2000, Abstract 232.
   Google Scholar
• Wheat J, Mawhinney S, Hafner R, et al. Treatment of histo-plasmosis with fluconazole in patients with the acquired im-munodeficiency syndrome. Am J Med 1997; 103: 336–342.
   Google Scholar
• Summary report of the national HIV seroprevalence survey of women attending public antenatal clinics in South Africa. Pre-toria: Department of Health, 2000.
   Google Scholar
• Liebowitz L, Crewe-Brown HH, Hoosen AA, Pillay DG, Roditi D and Biomic Study group of South Africa. In vitro susceptibil-ity of Candida species to Fluconazole. Proceedings of IUSTI STD/HIV 6th World Congress combined with 7th Joint Biennial Congress of the STD and ID Societies of Southern Africa, Sun City, South Africa, November 21–24, 1999. Johannesburg: Infectious Diseases Society of Southern Africa, 1999: Abstract IDP30.
   Google Scholar
• Ally R, Hassan H, Ahmed R, Segal I. Clinical and biochemical parameters in HIV positive patients with oesophageal candidia-sis. In: Proceedings of the South African Gastroenterology Soci-ety Congress, Stellenbosch, South Africa, October 2–6, 1998. Stellenbosch: South African Gastroenterology Society, 1998: Abstract.
   Google Scholar
• National Reference Centre for Sexually Transmitted Diseases. Report to the Department of Health on National Microbiolog-ical Surveillance, Johannesburg 1998.
   Google Scholar
• Moosa MYS, Coovadia YM. Cryptococcal meningitis in Dur-ban, South Africa: A comparison of clinical features, labora-tory findings and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin Infect Dis 1997; 24: 131–134.
   PubMed Web of Science ®Google Scholar
• Crewe-Brown HH, Karstaedt AS, Khoosal M, Bhagoobhai L, Ronin 0, Dromer F. A ten year study of cryptococcal meningi-tis. In: Proceedings of the 4th International Conference on Cryp-tococcus and Cryptococcosis, London, UK, September 11–16, 1999. London: International Society for Human and Animal Mycology, 1999: Abstract F6.
   Google Scholar
• Glassman SJ, Hale MJ. Cutaneous cryptococcosis and Kaposi's sarcoma occurring in the same lesions in a patient with the acquired immunodeficiency syndrome. Clin Exp Dermatol 1995; 20: 480–486.
   PubMedGoogle Scholar
• Hazelhurst JA, Fismer HF. Histoplasmosis presenting with unusual skin lesions in acquired immunodeficiency syndrome. Brit J Dermatol 1985; 113: 345–348.
   PubMedGoogle Scholar
• Pillay T, Pillay DG, Bramdev A. Disseminated histoplasmosis in a human immunodeficiency virus-infected African child. Pediatr Infect Dis J 1997; 16: 417–418.
   Google Scholar
• Wood R, Jackson T. Disseminated histoplasmosis in AIDS patients in South Africa: a report of 3 cases and review. South Afr J Epidemiol Infect 1997; 12: 72–74.
   Google Scholar
• Ramdial PK, Morar N, Naidoo DK, Dlova N, Aboobaker J. Cutaneous manifestations of human immunodeficiency virus infection. In: Proceedings of the 38th Annual Congress of the Federation of South African Societies of Pathology, Pretoria, June 28-July 1, 1998. Pretoria: Federation of South African Societies of Pathology, 1998: Abstract A22.
   Google Scholar
• Helm MAF, Berman C. The clinical, therapeutic and epidemio-logical features of sporotrichosis infection on the mines. In: Sporotrichosis Infection on Mines of the Witwatersrand, Johan-nesburg: The Transvaal Chamber of Mines, 1947: 41–67.
   Google Scholar
• Westermann K. HIV disease and the skin. Part II. Spec Med Dermatol 1999; 2: 105–109.
   Google Scholar